Edwards Lifesciences Corporation EW

86.29 0.56 0.65% as of 25 Sep
Market cap
$49.4B
P/E
49.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Edwards Lifesciences Corporation (EW) EV/EBITDA

As of 25 September 2026, Edwards Lifesciences Corporation (EW) trades at a EV/EBITDA of 28.6×. Over the past ten years it has ranged from 19.6× (December 2016) to 62.2× (June 2021); the current reading is higher than 44% of that period. That is above the Medical Devices industry median of 11.8× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 32.6× 22.10%
FY2024 26.7× (13.56%)
FY2023 30.8× 11.32%
FY2022 27.7× (36.72%)
FY2021 43.8× (21.47%)
FY2020 55.8× 44.51%
FY2019 38.6× (1.34%)
FY2018 39.1× 97.17%
FY2017 19.8× (14.78%)
FY2016 23.3× 0.57%

Quarterly

Period EV/EBITDA Change
Jun 2026 30.0× 4.56%
Mar 2026 28.7× (11.72%)
Dec 2025 32.6× 21.90%
Sep 2025 26.7× 1.93%
42 more quarters

Against its own ten years

Low 19.6× High 62.2×
Ten-year median 29.4×
Current reading's percentile 44

EV/EBITDA against peers

Company EV/EBITDA
PHG Koninklijke Philips N.V. compare 8.6×
ZBH Zimmer Biomet Holdings, Inc. compare 10.6×
GEHC GE HealthCare Technologies Inc. compare 11.9×
STE STERIS plc compare 13.4×
MDT Medtronic PLC compare 13.7×
BSX Boston Scientific Corporation compare 13.8×
SYK Stryker Corporation compare 17.2×
DXCM DexCom, Inc. compare 23.2×
EW Edwards Lifesciences Corporation 28.6×
Medical Devices industry median 11.8×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on EW